PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 22814394-0 2012 SJSZ glycoprotein (38 kDa) modulates expression of IL-2, IL-12, and IFN-gamma in cyclophosphamide-induced Balb/c. Cyclophosphamide 81-97 interleukin 2 Mus musculus 51-55 23659474-8 2013 Correspondingly, significantly higher secretion of perforin, granzyme B, IL-2, and IFN-gamma in tumor tissues with decreased tumor growth was seen in the cyclophosphamide injection group than in the control group. Cyclophosphamide 154-170 interleukin 2 Mus musculus 73-77 22667143-3 2012 The immunocompromised mice model was established by intraperitoneal injection cyclophosphamide to detected the content of IL-2, IL-6 in serum, CD4+, CD8+ in the peripheral blood by ELISA and flow cytometry, respectively. Cyclophosphamide 78-94 interleukin 2 Mus musculus 122-126 21649551-5 2012 Treatment of mice with CPA suppressed the formation of Th1 cytokines (TNF-alpha, IFN-gamma, and IL-2), shifting the overall balance toward Th2 (IL-4 and IL-5). Cyclophosphamide 23-26 interleukin 2 Mus musculus 96-100 23000689-6 2012 Along with the depletion of Tregs by low-dose CY treatment, the expression of interleukin-2 (IL-2) in T effector cells increased, and intracellular cAMP concentrations in immune cells decreased. Cyclophosphamide 46-48 interleukin 2 Mus musculus 78-91 23000689-6 2012 Along with the depletion of Tregs by low-dose CY treatment, the expression of interleukin-2 (IL-2) in T effector cells increased, and intracellular cAMP concentrations in immune cells decreased. Cyclophosphamide 46-48 interleukin 2 Mus musculus 93-97 18853118-6 2008 The level of IL-2 and INF-gamma could be decreased by Cy to 38.12+/-6.88 ng/L and 139.23+/-29.87 ng/L, respectively, while RIP in high dose could increase the secretion of IL-2 and INF-gamma to 53.54+/-14.43 ng/L and 189.91+/-32.63 ng/L, respectively. Cyclophosphamide 54-56 interleukin 2 Mus musculus 13-17 21279551-8 2011 The high-dose of zymosan markedly showed a depressant effect on S(180) tumor, enhanced by the action of Cy that increased mRNA expression levels of TNF-alpha and IL-2. Cyclophosphamide 104-106 interleukin 2 Mus musculus 162-166 19946662-7 2010 Administration of one dose of IL2-cas decreased the incidence of diabetes in NOD mice, showing a superior beneficial effect when administered at young age, and effectively blocked induction of hyperglycaemia by cyclophosphamide, reducing the severity of islet inflammation. Cyclophosphamide 211-227 interleukin 2 Mus musculus 30-33 18853118-6 2008 The level of IL-2 and INF-gamma could be decreased by Cy to 38.12+/-6.88 ng/L and 139.23+/-29.87 ng/L, respectively, while RIP in high dose could increase the secretion of IL-2 and INF-gamma to 53.54+/-14.43 ng/L and 189.91+/-32.63 ng/L, respectively. Cyclophosphamide 54-56 interleukin 2 Mus musculus 172-176 9174132-0 1997 Interleukin-2 increases intracellular glutathione levels and reverses the growth inhibiting effects of cyclophosphamide on B16 melanoma cells. Cyclophosphamide 103-119 interleukin 2 Mus musculus 0-13 17255288-8 2007 Optimal therapeutic responses to the transfer of immune cells were associated with the cyclophosphamide-mediated induction of a "cytokine storm" [including granulocyte macrophage colony-stimulating factor, interleukin (IL)-1beta, IL-7, IL-15, IL-2, IL-21, and IFN-gamma], occurring during the "rebound phase" after drug-induced lymphodepletion. Cyclophosphamide 87-103 interleukin 2 Mus musculus 243-247 10607705-1 2000 During recovery from intensive chemotherapy with cyclophosphamide (CTX), mice suffer a severe but transitory impairment in spleen cell proliferation to T-cell mitogens (Con A or anti-CD3 plus IL-2). Cyclophosphamide 49-65 interleukin 2 Mus musculus 192-196 9222281-11 1997 IL-2 administered on days 6-10 was therapeutically effective in this model when mice were treated with cyclophosphamide on day 6. Cyclophosphamide 103-119 interleukin 2 Mus musculus 0-4 10464704-0 1999 Enhanced antitumor immune responses of IL-2 gene-modified tumor vaccine by combination with IL-1 and low dose cyclophosphamide. Cyclophosphamide 110-126 interleukin 2 Mus musculus 39-43 10089919-10 1999 After 24 hours of in vitro IL-2 activation, the cytotoxic effector cell function of the Cy-mobilized PBSC population was lower than that of paclitaxel-mobilized cells when tested against three tumor cell lines (B16, melanoma; C1498, AML; and Yak-1, lymphoma). Cyclophosphamide 88-90 interleukin 2 Mus musculus 27-31 7759164-9 1995 Interleukin (IL)-2 added to pre-T3CS CD4-depleted ALT cells cultured with T3CS restored anti-tumor activity when combined with CY. Cyclophosphamide 127-129 interleukin 2 Mus musculus 0-18 8933279-9 1996 Substantial numbers of Th1 cells (positive for IFN-gamma, TNF-alpha, IL-2 and/or IL-2 receptor) were observed only after acceleration of diabetes development by a single injection of cyclophosphamide (250 mg/kg i.p.). Cyclophosphamide 183-199 interleukin 2 Mus musculus 69-73 8933279-9 1996 Substantial numbers of Th1 cells (positive for IFN-gamma, TNF-alpha, IL-2 and/or IL-2 receptor) were observed only after acceleration of diabetes development by a single injection of cyclophosphamide (250 mg/kg i.p.). Cyclophosphamide 183-199 interleukin 2 Mus musculus 81-85 8706342-9 1996 After peptide challenge of splenocytes in vitro, protection against CY-accelerated diabetes was associated with higher peptide-specific production of T helper type 2 (Th2)-associated interleukins 4 and 10, whereas Th1-associated interferon-gamma and IL-2 were proportionally less represented. Cyclophosphamide 68-70 interleukin 2 Mus musculus 250-254 7622294-0 1995 Correlation between the sensitivity or resistance to IL-2 and the response to cyclophosphamide of 4 tumors transplantable in the same murine host. Cyclophosphamide 78-94 interleukin 2 Mus musculus 53-57 7600560-7 1995 Thus, the addition of low-dose IL-2 (25 x 10(3) IU daily, from day 4 to day 7) to high-dose CY (300 mg/kg, days 3 and 8) significantly increased tumor growth in both the early and later periods, compared to the effect of CY alone. Cyclophosphamide 221-223 interleukin 2 Mus musculus 31-35 7860617-0 1995 Interleukin-2 gene therapy of residual EL-4 leukaemia potentiates the effect of cyclophosphamide pretreatment. Cyclophosphamide 80-96 interleukin 2 Mus musculus 0-13 7860617-1 1995 Experiments were designed to investigate a possible therapeutic role of interleukin-2 (IL-2) gene transfer in the model of murine (EL-4) leukaemia pretreated with cyclophosphamide. Cyclophosphamide 163-179 interleukin 2 Mus musculus 87-91 8168119-7 1994 In bulk cultures containing IL-2 (1000 CU/ml, 3-4 days), both 5-FU and CY reduced LAK activity of euthymic mice splenocytes for up to 6 days after chemotherapy, which was followed on day 9 by full recovery. Cyclophosphamide 71-73 interleukin 2 Mus musculus 28-32 7804526-6 1994 (b) In mice with advanced metastatic carcinoma previously treated with chemotherapy (cyclophosphamide), the survival was two to six times greater following administration of SSL-IL-2 as compared with IL-2 (p < 0.05; log-rank test). Cyclophosphamide 85-101 interleukin 2 Mus musculus 178-182 8010605-2 1994 The enhancement of antibody response was associated with increased induction of T helper cell activity and IL-2 production as evidenced in mice immunodepressed by aging or by cyclophosphamide treatment. Cyclophosphamide 175-191 interleukin 2 Mus musculus 107-111 8168119-6 1994 In euthymic mice injected with IL-2 (5 x 10(4) Cetus units twice daily for 4-5 days), 5-FU augmented (up to 37-fold, days 1-9) and CY reduced (up to day 6) LAK activity, as compared with that in the IL-2 control. Cyclophosphamide 131-133 interleukin 2 Mus musculus 31-35 7974716-0 1994 The inhibitory effect of cyclophosphamide-induced MAC-1+ natural suppressor cells on IL-2 and IL-4 utilization in MLR. Cyclophosphamide 25-41 interleukin 2 Mus musculus 85-89 1835471-6 1991 IL-2 prevented neutropenia and exacerbated lymphopenia caused by cyclophosphamide. Cyclophosphamide 65-81 interleukin 2 Mus musculus 0-4 1835471-5 1991 The median numbers of translocated E. coli C25/g of mesenteric lymph node were significantly (P less than .005) higher after both 3 days (659 vs. 117) and 5 days (550 vs. 50) of treatment with IL-2 with cyclophosphamide and after 5 days (1784 vs. 225) of IL-2 without cyclophosphamide. Cyclophosphamide 203-219 interleukin 2 Mus musculus 193-197 1835471-5 1991 The median numbers of translocated E. coli C25/g of mesenteric lymph node were significantly (P less than .005) higher after both 3 days (659 vs. 117) and 5 days (550 vs. 50) of treatment with IL-2 with cyclophosphamide and after 5 days (1784 vs. 225) of IL-2 without cyclophosphamide. Cyclophosphamide 268-284 interleukin 2 Mus musculus 193-197 8425189-6 1993 Combined IL-1 beta/IL-2 treatment dampened the decrease and accelerated the recovery of myeloid cells after cyclophosphamide injection, whereas the single cytokine regimen was not effective. Cyclophosphamide 108-124 interleukin 2 Mus musculus 19-23 1534792-2 1992 The enhancement of the antibody response is associated with increased induction of T helper cell activity and IL-2 production, as evidenced in mice immunodepressed by aging or by cyclophosphamide treatment. Cyclophosphamide 179-195 interleukin 2 Mus musculus 110-114 1361881-7 1992 Thus, a triple regimen using TSTA, CY, and IS-IL-2 appears to augment CTL induction in tumor-bearing hosts undergoing stimulation of helper elements by TSTA and inhibition of suppressor cells by CY. Cyclophosphamide 195-197 interleukin 2 Mus musculus 46-50 1835471-9 1991 Thus, IL-2 unexpectedly enhanced the translocation of E. coli C25 from the gastrointestinal tracts of both cyclophosphamide-pretreated and normal mice. Cyclophosphamide 107-123 interleukin 2 Mus musculus 6-10 1760819-1 1991 We investigated the in vivo effects of cyclophosphamide (CY) on interleukin-2(IL-2)-induced cytolytic function and spleen cell immunophenotype. Cyclophosphamide 57-59 interleukin 2 Mus musculus 64-77 1991327-2 1991 The results of this study indicate that pretreatment in vitro (100 ng/ml for 1 hr) or in vivo (200 micrograms/kg/day for 4 days) with thymosin alpha 1 (TA1), significantly increased the IL-2 (from 100 to 500 U/ml) in vitro induced cytotoxic activity of spleen lymphocytes, collected from both normal and cyclophosphamide and tumor-suppressed animals, against both YAC-1 (NK sensitive) and MBL-2 (NK resistant) cell lines. Cyclophosphamide 304-320 interleukin 2 Mus musculus 186-190 1760819-0 1991 Importance in timing of cyclophosphamide on the enhancement of interleukin-2-induced cytolysis. Cyclophosphamide 24-40 interleukin 2 Mus musculus 63-76 1760819-8 1991 These findings provide evidence that CY may be used more effectively in IL-2-based immunotherapy protocols, if consideration is given to timing of CY and IL-2 administration. Cyclophosphamide 37-39 interleukin 2 Mus musculus 72-76 34949747-7 2022 In addition, GBP significantly stimulated mRNA expression levels of immune-associated genes including interleukin-1beta (IL-1beta), IL-2, IL-4, IL-6, tumor necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma), Toll-like receptor 4 (TLR-4), and cyclooxygenase-2 (COX-2) in CY-treated mice. Cyclophosphamide 283-285 interleukin 2 Mus musculus 132-136 1718146-2 1990 PSP 25 mg/kg ip into mice for 5 d antagonized the inhibition of IL-2 production by cyclophosphamide from activated T lymphocytes and restored the suppressed T-cell-mediated delayed, type hypersensitivity response to normal. Cyclophosphamide 83-99 interleukin 2 Mus musculus 64-68 2389941-5 1990 Treatment with cultured killer cells and in vivo IL 2 after immunochemotherapy (immunostimulator followed by CPA) was the most effective protocol in which immunostimulator, chemotherapy, killer cells and IL 2 respectively seemed to induce, regulate, supplement and amplify anti-tumor effector cells. Cyclophosphamide 109-112 interleukin 2 Mus musculus 49-53 34840584-8 2021 CPP upregulated the contents of cytokines (IL-2, IL-6, IFN-gamma, and TNF-alpha) in serum, which were downregulated by cyclophosphamide. Cyclophosphamide 119-135 interleukin 2 Mus musculus 43-47 6334139-2 1984 Treatment of conventional mice implanted with lung and mammary carcinomas by repeated administration of low-dose cyclophosphamide (CY), IL-2, and tumor-sensitized CTC resulted in delayed tumor onset, retarded tumor growth rate, prolonged survival, and a higher cure rate as compared with mice receiving only CY. Cyclophosphamide 308-310 interleukin 2 Mus musculus 136-140 34128029-4 2021 The results demonstrated that treatment with AH could prevent the reduction in spleen and thymus indices as well as body weight, and significantly increase the Peyer"s patch count in CY-induced mice and the levels of IL-2, IL-6, and TNF-alpha in serum, suggesting the role of Alhagi honey polysaccharides in alleviating the immunosuppression induced by CY. Cyclophosphamide 353-355 interleukin 2 Mus musculus 217-221 2895062-0 1988 Lethal vaccinia infection in cyclophosphamide-suppressed mice is associated with decreased expression of Thy-1, Lyt-2 and L3T4 and diminished IL-2 production in surviving T cells. Cyclophosphamide 29-45 interleukin 2 Mus musculus 142-146 3501452-3 1987 When a combination chemotherapy which consisted of cisplatin, adriamycin and cyclophosphamide was given to these ovarian cancer patients, the OKT 4/8 cell ratio was significantly increased while the IL-2 production was markedly inhibited. Cyclophosphamide 77-93 interleukin 2 Mus musculus 199-203 2875791-12 1986 Furthermore, chemoimmunotherapy including intrasplenic IL-2 injection potentiated the antitumor immunity achieved with combined tumor-specific transplantation antigen and cyclophosphamide. Cyclophosphamide 171-187 interleukin 2 Mus musculus 55-59 2666309-4 1989 Detectable levels of IL-2 in these mitogen-stimulated supernatants began to rise after Day 25, which was temporally associated with a gradual shift from active immunity, to immunity mediated by cyclophosphamide-resistant memory T cells, which did not absorb IL-2 in vitro. Cyclophosphamide 194-210 interleukin 2 Mus musculus 21-25 2785003-6 1989 A synergistic therapeutic effect was achieved in mice with the solid tumors, but not in mice with the lymphoma, only when IL-2 was given 1-4 days after cyclophosphamide (100-200 mg/kg). Cyclophosphamide 152-168 interleukin 2 Mus musculus 122-126 2785003-7 1989 Conversely, administration of IL-2 1-4 days prior to cyclophosphamide resulted, in all three tumor systems, in enhanced tumor growth and in decreased survival as compared with mice receiving cyclophosphamide alone. Cyclophosphamide 53-69 interleukin 2 Mus musculus 30-34 2785003-7 1989 Conversely, administration of IL-2 1-4 days prior to cyclophosphamide resulted, in all three tumor systems, in enhanced tumor growth and in decreased survival as compared with mice receiving cyclophosphamide alone. Cyclophosphamide 191-207 interleukin 2 Mus musculus 30-34 2785003-8 1989 Similarly, treatment with IL-2 both before and after cyclophosphamide was less efficacious than a single course of IL-2 given afterwards. Cyclophosphamide 53-69 interleukin 2 Mus musculus 26-30 3264714-10 1988 The effect was further enhanced by a second dose of CY at the end of a course of IL-2. Cyclophosphamide 52-54 interleukin 2 Mus musculus 81-85 3260132-0 1988 Improved therapeutic effects of interleukin 2 after the accumulation of lymphokine-activated killer cells in tumor tissue of mice previously treated with cyclophosphamide. Cyclophosphamide 154-170 interleukin 2 Mus musculus 32-45 3260132-6 1988 Satisfactory effects from the combination of CY and IL-2 were also obtained by 5 days administration of IL-2 between days 11 and 15, initiated 6 days after CY treatment, but not by that given before CY (days 1-5) or 1 day after CY (days 6-10). Cyclophosphamide 45-47 interleukin 2 Mus musculus 104-108 3260132-6 1988 Satisfactory effects from the combination of CY and IL-2 were also obtained by 5 days administration of IL-2 between days 11 and 15, initiated 6 days after CY treatment, but not by that given before CY (days 1-5) or 1 day after CY (days 6-10). Cyclophosphamide 156-158 interleukin 2 Mus musculus 52-56 3260132-6 1988 Satisfactory effects from the combination of CY and IL-2 were also obtained by 5 days administration of IL-2 between days 11 and 15, initiated 6 days after CY treatment, but not by that given before CY (days 1-5) or 1 day after CY (days 6-10). Cyclophosphamide 156-158 interleukin 2 Mus musculus 104-108 3260132-6 1988 Satisfactory effects from the combination of CY and IL-2 were also obtained by 5 days administration of IL-2 between days 11 and 15, initiated 6 days after CY treatment, but not by that given before CY (days 1-5) or 1 day after CY (days 6-10). Cyclophosphamide 156-158 interleukin 2 Mus musculus 52-56 3260132-6 1988 Satisfactory effects from the combination of CY and IL-2 were also obtained by 5 days administration of IL-2 between days 11 and 15, initiated 6 days after CY treatment, but not by that given before CY (days 1-5) or 1 day after CY (days 6-10). Cyclophosphamide 156-158 interleukin 2 Mus musculus 104-108 3260132-6 1988 Satisfactory effects from the combination of CY and IL-2 were also obtained by 5 days administration of IL-2 between days 11 and 15, initiated 6 days after CY treatment, but not by that given before CY (days 1-5) or 1 day after CY (days 6-10). Cyclophosphamide 156-158 interleukin 2 Mus musculus 52-56 3260132-6 1988 Satisfactory effects from the combination of CY and IL-2 were also obtained by 5 days administration of IL-2 between days 11 and 15, initiated 6 days after CY treatment, but not by that given before CY (days 1-5) or 1 day after CY (days 6-10). Cyclophosphamide 156-158 interleukin 2 Mus musculus 104-108 3257159-3 1988 Cy at doses of 100 mg/kg and 150 mg/kg completely protected mice from a 100% lethal dose of IL-2, and doses of 50 mg/kg and 150 mg/kg allowed the administration of a median of 4.5 and 10.0 more doses of IL-2, respectively, before death from IL-2 toxicity occurred. Cyclophosphamide 0-2 interleukin 2 Mus musculus 92-96 3257159-3 1988 Cy at doses of 100 mg/kg and 150 mg/kg completely protected mice from a 100% lethal dose of IL-2, and doses of 50 mg/kg and 150 mg/kg allowed the administration of a median of 4.5 and 10.0 more doses of IL-2, respectively, before death from IL-2 toxicity occurred. Cyclophosphamide 0-2 interleukin 2 Mus musculus 203-207 3257159-3 1988 Cy at doses of 100 mg/kg and 150 mg/kg completely protected mice from a 100% lethal dose of IL-2, and doses of 50 mg/kg and 150 mg/kg allowed the administration of a median of 4.5 and 10.0 more doses of IL-2, respectively, before death from IL-2 toxicity occurred. Cyclophosphamide 0-2 interleukin 2 Mus musculus 203-207 3257159-5 1988 In mice bearing pulmonary metastases of the weakly immunogenic MCA-105 sarcoma, IL-2 increased median survival time from 33 (no IL-2) to greater than 60 days for all doses of IL-2 tested when combined with a single injection of Cy at 75 mg/kg (P less than 0.002). Cyclophosphamide 228-230 interleukin 2 Mus musculus 80-84 2444243-5 1987 High doses of IL-2 or pretreatment with cyclophosphamide restored the efficacy of IL-2 and LAK cell immunotherapy. Cyclophosphamide 40-56 interleukin 2 Mus musculus 82-86 2949833-9 1987 After Cy treatment, the proliferative ability of spleen cells in response to interleukin-2 (IL-2) was substantially impaired. Cyclophosphamide 6-8 interleukin 2 Mus musculus 77-90 2949833-9 1987 After Cy treatment, the proliferative ability of spleen cells in response to interleukin-2 (IL-2) was substantially impaired. Cyclophosphamide 6-8 interleukin 2 Mus musculus 92-96 2949833-10 1987 Using monoclonal antibodies to the IL-2 receptor, we found that Cy-treated T lymphocytes failed to fully express the IL-2 receptor following in vitro stimulation with irradiated tumor cells. Cyclophosphamide 64-66 interleukin 2 Mus musculus 35-39 3489291-4 1986 The combination of TIL and cyclophosphamide was further potentiated by the simultaneous administration of IL-2. Cyclophosphamide 27-43 interleukin 2 Mus musculus 106-110 2428762-6 1986 Administration of isoprinosine every day (50 mg/kg) augmented Con A induced mitogenesis, IL-2 production and NK activity in animals treated with cyclophosphamide, but not in normal mice. Cyclophosphamide 145-161 interleukin 2 Mus musculus 89-93 6134774-2 1983 Similarly, IL 2 delivered in vivo in a rate-controlled manner enhances cytotoxic activity in mice that are immunosuppressed by high doses of CY. Cyclophosphamide 141-143 interleukin 2 Mus musculus 11-15 6334139-6 1984 IL-2 injections into normal, untreated, as well as X-irradiated or CY-treated mice, resulted in enhanced natural cytotoxicity and cytotoxic responsiveness in vitro to syngeneic tumors, greater proliferative response to phytohemagglutinin, and a tendency toward depressed proliferative responses to concanavalin A and to allogeneic leukocytes. Cyclophosphamide 67-69 interleukin 2 Mus musculus 0-4 6334140-8 1984 Elevated quantities of TCGF (up to threefold) were generated by TBS of mice pretreated in vivo 1-4 days previously with low doses of either cyclophosphamide or X-irradiation, with or without IND. Cyclophosphamide 140-156 interleukin 2 Mus musculus 23-27 6178678-1 1982 This brief review of our experiments concerning the in vivo activity of crude Il-2 led us to the following conclusion: The first is the existence, in vivo, of a cyclophosphamide-sensitive T-cell controlling the activity of a serum born Il-2 inhibitor in thymus-bearing normal mice. Cyclophosphamide 161-177 interleukin 2 Mus musculus 78-82 6178678-1 1982 This brief review of our experiments concerning the in vivo activity of crude Il-2 led us to the following conclusion: The first is the existence, in vivo, of a cyclophosphamide-sensitive T-cell controlling the activity of a serum born Il-2 inhibitor in thymus-bearing normal mice. Cyclophosphamide 161-177 interleukin 2 Mus musculus 236-240 33266362-5 2020 Oral administration of live K040706 prevented the CYP-induced decreases in body weight, thymus index, natural killer (NK) cell activity, T and B cell proliferation, and cytokine (interferon (IFN)-gamma, interleukin (IL)-2, and IL-12) production. Cyclophosphamide 50-53 interleukin 2 Mus musculus 203-221 6790656-0 1981 Lyt-23+ cyclophosphamide-sensitive T cells regulate the activity of an interleukin 2 inhibitor in vivo. Cyclophosphamide 8-24 interleukin 2 Mus musculus 71-84 6790656-2 1981 Evidence is presented that cyclophosphamide-sensitive Lyt-23+ T cells induce high II-2 inhibitor activity in the recipient nu/nu mice in the course of a graft-vs.-host reaction. Cyclophosphamide 27-43 interleukin 2 Mus musculus 82-86 32475918-7 2020 PSP elevated the CD4+/CD8+ ratio is a dose-dependent manner and increased the levels of interleukin-2 (IL-2) and tumor necrosis factor-alpha (TNF-alpha) in the sera of Cy-treated mice. Cyclophosphamide 168-170 interleukin 2 Mus musculus 88-101 32306006-13 2020 In addition, the Fei-Liu-Ping ointment + cyclophosphamide group"s cell apoptosis increased significantly compared with saline group and there were significant differences on expressions of HIF-1alpha, Bcl-2, Bax, Caspase-3, IL-2 for this group compared with saline group. Cyclophosphamide 41-57 interleukin 2 Mus musculus 224-228 32475918-7 2020 PSP elevated the CD4+/CD8+ ratio is a dose-dependent manner and increased the levels of interleukin-2 (IL-2) and tumor necrosis factor-alpha (TNF-alpha) in the sera of Cy-treated mice. Cyclophosphamide 168-170 interleukin 2 Mus musculus 103-107 30268651-10 2019 Moreover, XMT-WE promoted the secretion of interleukin-2 (IL-2) and interferon-gamma (IFN-gamma) in cyclophosphamide (CTX)-induced immunosuppressive mice. Cyclophosphamide 100-116 interleukin 2 Mus musculus 58-62 28939510-6 2018 In addition, PSP treatment restored the levels of IL-2, TNF-alpha, IL-8 and IL-10 in the serum of the Cy-treated mice in a dose-dependent manner. Cyclophosphamide 102-104 interleukin 2 Mus musculus 50-54 25708328-0 2015 Chronodependent effect of interleukin-2 on mouse spleen cells in the model of cyclophosphamide immunosuppression. Cyclophosphamide 78-94 interleukin 2 Mus musculus 26-39 25708328-1 2015 We studied the chronodependent effect of IL-2 in the experimental model of immunodeficiency, cyclophosphamide-induced immunosuppression in mice. Cyclophosphamide 93-109 interleukin 2 Mus musculus 41-45 25708328-2 2015 IL-2 in a dose of 100 U/ mouse was administered at 10.00 and 16.00 for 3 days after injection of cyclophosphamide. Cyclophosphamide 97-113 interleukin 2 Mus musculus 0-4 25785030-4 2015 Results showed that SCVP and CVP can overcome CY-induced immunosuppression by promoting spleen lymphocyte proliferation, raising serum IFN-gamma and IL-2 levels, enlarging immune organ indexes, and decreasing excessive apoptosis. Cyclophosphamide 46-48 interleukin 2 Mus musculus 149-153